Related Experiment Video
Updated: Jul 18, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Functional analysis of two abnormal antithrombin proteins with different intracellular kinetics
Yuta Imai1, Satomi Nagaya1, Yuhei Araiso1
1Department of Clinical Laboratory Science, Division of Health Sciences, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Two novel antithrombin (AT) variants causing venous thrombosis impair AT secretion and transport. These findings clarify type I AT deficiency mechanisms and aid therapy development.
Area of Science:
- Genetics
- Molecular Biology
- Hematology
Background:
- Hereditary antithrombin (AT) deficiency type I is linked to venous thrombosis.
- Decreased AT antigen levels in blood are characteristic of this deficiency.
Purpose of the Study:
- To analyze the mechanism by which novel and known abnormal AT variants cause type I AT deficiency.
- To investigate the cellular processing and secretion of identified AT variants.
Main Methods:
- Constructed and expressed wild-type and variant AT vectors in human embryonic kidney 293 cells.
- Evaluated AT antigen levels and N-glycosylation using western blot analysis.
- Examined subcellular co-localization and degradation pathways via confocal microscopy and chase experiments.
Main Results:
- Identified a novel variant (c.613delC) and a known variant (c.283T>C).
- Both variants showed reduced extracellular secretion with normal N-glycosylation.
- Impaired transport to the Golgi apparatus and differential degradation pathways (proteasomal for c.613delC, ER retention for c.283T>C) were observed.
Conclusions:
- Identified AT variants lead to suppressed secretion and impaired ER-Golgi transport.
- These findings elucidate the mechanism of type I AT deficiency.
- Provides insights for future therapy development for AT deficiency.
More Related Videos
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care

